...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Sao Paulo Medical Journal >Estrogen and progesterone receptor testing in breast carcinoma: concordance of results between local and reference laboratories in Brazil
【24h】

Estrogen and progesterone receptor testing in breast carcinoma: concordance of results between local and reference laboratories in Brazil

机译：乳腺癌中雌激素和孕激素受体测试：巴西当地实验室与参考实验室之间的结果一致性

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

CONTEXT AND OBJECTIVE: Breast cancer accounts for approximately one quarter of all cancers in females. Estrogen and progesterone receptor testing has become an essential part of the clinical evaluation of breast carcinoma patients, and accurate results are critical in identifying patients who may benefit from hormone therapy. The present study had the aim of investigating the concordance of the results from hormone receptor tests between a reference laboratory and local (or community) laboratories in Brazil. DESIGN AND SETTING: Retrospective study at a reference pathology laboratory. METHODS: The concordance in the results from hormone receptor tests between a reference laboratory and 146 local laboratories in Brazil was compared in relation to 500 invasive breast carcinoma cases, using immunohistochemistry. RESULTS: There was concordance in 89.4% (447/500 cases) and 85.0% (425/500 cases) of the results from estrogen (κ = 0.744, P < 0.001) and progesterone (κ = 0.688, P < 0.001) receptor tests, respectively, between local and reference laboratories. This was similar to findings in other countries. The false negative rates from estrogen and progesterone receptor tests in local laboratories were 8.7% and 14.4%, respectively. The false positive rates from estrogen and progesterone receptor tests in local laboratories were 15.5% and 16.0%, respectively. CONCLUSION: Technical and result interpretation issues may explain most of the discordances in hormone receptor testing in local laboratories. Validation of estrogen and progesterone receptor tests at local laboratories, with rigorous quality control measures, is strongly recommended in order to avoid erroneous treatment of breast cancer patients.
机译：背景与目的：乳腺癌约占女性所有癌症的四分之一。雌激素和孕激素受体测试已成为乳腺癌患者临床评估的重要组成部分，准确的结果对于确定可能受益于激素治疗的患者至关重要。本研究的目的是调查参考实验室与巴西当地（或社区）实验室之间的激素受体测试结果的一致性。设计与设置：在参考病理实验室进行回顾性研究。方法：使用免疫组织化学方法，比较了500例浸润性乳腺癌患者中，参考实验室与巴西146个本地实验室之间的激素受体测试结果的一致性。结果：雌激素（κ= 0.744，P <0.001）和孕激素（κ= 0.688，P <0.001）受体测试的结果分别为89.4％（447/500例）和85.0％（425/500例）分别在本地实验室和参考实验室之间。这与其他国家的调查结果相似。在当地实验室，雌激素和孕激素受体检测的假阴性率分别为8.7％和14.4％。在当地实验室，雌激素和孕激素受体检测的假阳性率分别为15.5％和16.0％。结论：技术和结果解释问题可能解释了当地实验室激素受体检测的大多数不一致性。强烈建议在当地实验室通过严格的质量控制措施来验证雌激素和孕激素受体测试，以避免对乳腺癌患者的错误治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号